Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22863221 | 0.90 | ALOX5 (0.33) | ALOX5NR1I2AKT1 | |
| SCHEMBL22863234 | 0.82 | ALOX5 (0.36) | KDM4EALDH1A1HPGDALOX5NR1I2 | |
| SCHEMBL23941206 | 0.82 | ALOX5 (0.36) | KDM4EALDH1A1HPGDALOX5NR1I2 | |
| SCHEMBL22863201 | 0.81 | ALOX5 (0.35) | KDM4EALDH1A1HPGDALOX5PTGER4 | |
| SCHEMBL23941210 | 0.81 | ALOX5 (0.35) | KDM4EALDH1A1HPGDALOX5PTGER4 | |
| SCHEMBL22863225 | 0.81 | KDM4E (0.33) | KDM4EALDH1A1HPGDALOX5PTGER4 | |
| SCHEMBL22863342 | 0.80 | PTPN2 (0.38) | KDM4EALDH1A1HPGDALOX5PTGER4 | |
| SCHEMBL22863208 | 0.80 | ALOX5 (0.42) | ALOX5NR1I2 | |
| SCHEMBL22863212 | 0.77 | ALOX5 (0.36) | ALOX5NR1I2AKT1 | |
| SCHEMBL21538195 | 0.76 | ALOX5 (0.35) | ALOX5AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SHOWA UNIVERSITY (JP) | 2022-07-14 | — | — | US | disclosed |
| US-20210322381-A1 | DRUG FOR TREATMENT OR PREVENTION OF BLOOD CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2021-10-21 | — | — | US | disclosed |
| US-20210000794-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | SHOWA UNIVERSITY (JP) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322381-A1 | DRUG FOR TREATMENT OR PREVENTION OF BLOOD CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | PROC, FABP7, TIMP3 | KDM4E 2773/4885ALDH1A1 911/4885HPGD 197/4885 |
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SLC5A2, SLC5A1, IAPP | KDM4E 2764/4885ALDH1A1 342/4885HPGD 390/4885 |
| US-20210000794-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | REN, ATP6V1B1, SLC10A1 | KDM4E 3932/4885ALDH1A1 571/4885HPGD 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.